Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.37 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.37 |
| ▸ | PRMT1 | Q99873 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.36 |
| ▸ | PAOX | Q6QHF9 | 2/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | CA12 | O43570 | 1/20 | 0.34 |
| ▸ | CA1 | P00915 | 1/20 | 0.34 |
| ▸ | CA2 | P00918 | 1/20 | 0.34 |
| ▸ | CA9 | Q16790 | 1/20 | 0.34 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.34 |
| ▸ | IDO1 | P14902 | 1/20 | 0.34 |
| ▸ | EPHX1 | P07099 | 2/20 | 0.33 |
| ▸ | ALDH1A2 | O94788 | 1/20 | 0.33 |
| ▸ | ALDH2 | P05091 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5128168 | 0.98 | KDM4E (0.41) | MEN1KMT2AKDM4EMAPK1HIF1A | |
| SCHEMBL15328337 | 0.95 | MEN1 (0.36) | MEN1KMT2AKDM4EMAPK1HIF1A | |
| SCHEMBL27596164 | 0.90 | ALDH1A1 (0.37) | KMT2AMAPK1ALDH1A1TSHRIDO1 | |
| SCHEMBL21127531 | 0.82 | CA1 (0.42) | MEN1KMT2AKDM4EMAPK1HIF1A | |
| SCHEMBL16024409 | 0.82 | CA1 (0.42) | MEN1KMT2AKDM4EMAPK1HIF1A | |
| SCHEMBL3174690 | 0.82 | KDM4E (0.50) | MEN1KMT2AKDM4EMAPK1HIF1A | |
| SCHEMBL3280998 | 0.79 | PRMT1 (0.50) | KMT2AMAPK1PRMT1TSHRCA1 | |
| SCHEMBL28810302 | 0.79 | PRMT1 (0.35) | MEN1KMT2AKDM4EMAPK1HIF1A | |
| SCHEMBL15871737 | 0.79 | KDM4E (0.55) | MEN1KMT2AKDM4EMAPK1HIF1A | |
| SCHEMBL453216 | 0.79 | KDM4E (0.55) | MEN1KMT2AKDM4EMAPK1HIF1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080045524-A1 | Selective NPY (Y5) antagonists | H. LUNDBECK A/S (DK) | 2008-02-21 | — | — | US | disclosed |
| US-7273880-B2 | Selective NPY (Y5) antagonists | H. LUNBECK A/S (DK) | 2007-09-25 | — | — | US | disclosed |
| EP-1816127-A1 | TRIAZINE DERIVATIVES FOR USE AS SELECTIVE NPY (Y5) ANTAGONISTS | H. Lundbeck A/S (DK) | 2007-08-08 | — | — | EP | disclosed |
| EP-1183245-B1 | SELECTIVE NPY (Y5) ANTAGONISTS | LUNDBECK & CO AS H (DK) | 2007-05-09 | — | — | EP | disclosed |
| US-7189720-B2 | Selective NPY (Y5) antagonists | H. LUNDBECK A/S (DK) | 2007-03-13 | — | — | US | disclosed |
| US-6989379-B1 | Selective NPY (Y5) antagonists | H. LUNDBICK A/S (DK) | 2006-01-24 | — | — | US | disclosed |
| EP-1194421-B1 | SELECTIVE NPY (Y5) ANTAGONISTS | LUNDBECK & CO AS H (DK) | 2005-10-12 | — | — | EP | disclosed |
| US-20050176709-A1 | Selective NPY (Y5) antagonists | H. LUNDBECK A/S (DK) | 2005-08-11 | — | — | US | disclosed |
| US-20050137240-A1 | Selective NPY (Y5) antagonists | H. LUNDBECK A/S (DK) | 2005-06-23 | — | — | US | disclosed |
| EP-1194421-A4 | SELECTIVE NPY (Y5) ANTAGONISTS | SYNAPTIC PHARMA CORP (US) | 2002-09-11 | — | — | EP | disclosed |
| EP-1194421-A1 | SELECTIVE NPY (Y5) ANTAGONISTS | SYNAPTIC PHARMACEUTICAL CORPORATION (US) | 2002-04-10 | — | — | EP | disclosed |
| US-6225330-B1 | Selective NPY (Y5) antagonists (tricyclics) | SYNAPTIC PHARMACEUTICAL CORPORATION | 2001-05-01 | — | — | US | disclosed |
| US-6222040-B1 | FOR THERAPY OF EATING DISORDERS | SYNAPTIC PHARMACEUTICAL CORPORATION | 2001-04-24 | — | — | US | disclosed |
| WO-2001002379-A1 | SELECTIVE NPY (Y5) ANTAGONISTS | SYNAPTIC PHARMACEUTICAL CORPORATION (US) | 2001-01-11 | — | — | WO | disclosed |
| US-6124331-A | TREATING ABNORMAL FEEDING DISORDERS (OBESITY AND BULIMIA NERVOSA), SEXUAL/REPRODUCTIVE DISORDERS, DEPRESSION, EPILEPTIC SEIZURE, HYPERTENSION, CEREBRAL HEMORRHAGE, CONGESTIVE HEART FAILURE, SLEEP DISTURBANCES | SYNAPTIC PHARMACEUTICAL CORPORATION (US) | 2000-09-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080045524-A1 | Selective NPY (Y5) antagonists | NPY5R, NPY1R, NPY2R | MEN1 3247/4885KMT2A 3078/4885KDM4E 996/4885 |
| US-20050176709-A1 | Selective NPY (Y5) antagonists | NPY5R, NPY1R, NPY2R | MEN1 3247/4885KMT2A 3078/4885KDM4E 996/4885 |
| US-20050137240-A1 | Selective NPY (Y5) antagonists | NPY5R, NPY1R, NPY2R | MEN1 3281/4885KMT2A 3383/4885KDM4E 1066/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.